Annual EBITDA
-$70.54 M
+$4.15 M+5.56%
31 December 2023
Summary:
Achilles Therapeutics annual earnings before interest, taxes, depreciation & amortization is currently -$70.54 million, with the most recent change of +$4.15 million (+5.56%) on 31 December 2023. During the last 3 years, it has fallen by -$9.63 million (-15.82%). ACHL annual EBITDA is now -423.58% below its all-time high of -$13.47 million, reached on 31 December 2019.ACHL EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$20.42 M
-$2.62 M-14.71%
01 September 2024
Summary:
Achilles Therapeutics quarterly earnings before interest, taxes, depreciation & amortization is currently -$20.42 million, with the most recent change of -$2.62 million (-14.71%) on 01 September 2024. Over the past year, it has dropped by -$2.05 million (-11.17%). ACHL quarterly EBITDA is now -273.32% below its all-time high of -$5.47 million, reached on 31 March 2020.ACHL Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$69.70 M
-$1.32 M-1.93%
01 September 2024
Summary:
Achilles Therapeutics TTM earnings before interest, taxes, depreciation & amortization is currently -$69.70 million, with the most recent change of -$1.32 million (-1.93%) on 01 September 2024. Over the past year, it has increased by +$3.30 million (+4.52%). ACHL TTM EBITDA is now -1174.47% below its all-time high of -$5.47 million, reached on 31 March 2020.ACHL TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ACHL EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | -11.2% | +4.5% |
| 3 y3 years | -15.8% | -15.8% | -14.4% |
| 5 y5 years | -423.6% | - | - |
ACHL EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -15.8% | +5.6% | -55.6% | +7.2% | -14.4% | +9.1% |
| 5 y | 5 years | -423.6% | +5.6% | -273.3% | +7.2% | -1174.5% | +9.1% |
| alltime | all time | -423.6% | +5.6% | -273.3% | +7.2% | -1174.5% | +9.1% |
Achilles Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$20.42 M(+14.7%) | -$69.70 M(+1.9%) |
| June 2024 | - | -$17.80 M(+35.7%) | -$68.38 M(-0.4%) |
| Mar 2024 | - | -$13.12 M(-28.6%) | -$68.67 M(-5.9%) |
| Dec 2023 | -$70.54 M(-5.6%) | -$18.37 M(-3.8%) | -$73.00 M(-4.7%) |
| Sept 2023 | - | -$19.10 M(+5.5%) | -$76.64 M(+5.4%) |
| June 2023 | - | -$18.09 M(+3.7%) | -$72.68 M(-2.1%) |
| Mar 2023 | - | -$17.45 M(-20.7%) | -$74.22 M(-0.6%) |
| Dec 2022 | -$74.69 M | -$22.00 M(+45.3%) | -$74.69 M(+6.2%) |
| Sept 2022 | - | -$15.14 M(-22.9%) | -$70.31 M(+0.3%) |
| June 2022 | - | -$19.63 M(+9.6%) | -$70.08 M(+6.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2022 | - | -$17.92 M(+1.7%) | -$65.90 M(+8.2%) |
| Dec 2021 | -$60.91 M(+84.8%) | -$17.62 M(+18.2%) | -$60.91 M(+9.1%) |
| Sept 2021 | - | -$14.91 M(-3.6%) | -$55.80 M(+13.4%) |
| June 2021 | - | -$15.46 M(+19.7%) | -$49.20 M(+20.9%) |
| Mar 2021 | - | -$12.92 M(+3.2%) | -$40.68 M(+22.4%) |
| Dec 2020 | -$32.95 M(+144.6%) | -$12.52 M(+50.8%) | -$33.23 M(+60.5%) |
| Sept 2020 | - | -$8.30 M(+19.6%) | -$20.71 M(+66.9%) |
| June 2020 | - | -$6.94 M(+26.9%) | -$12.41 M(+126.9%) |
| Mar 2020 | - | -$5.47 M | -$5.47 M |
| Dec 2019 | -$13.47 M | - | - |
FAQ
- What is Achilles Therapeutics annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Achilles Therapeutics?
- What is Achilles Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Achilles Therapeutics?
- What is Achilles Therapeutics quarterly EBITDA year-on-year change?
- What is Achilles Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Achilles Therapeutics?
- What is Achilles Therapeutics TTM EBITDA year-on-year change?
What is Achilles Therapeutics annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of ACHL is -$70.54 M
What is the all time high annual EBITDA for Achilles Therapeutics?
Achilles Therapeutics all-time high annual earnings before interest, taxes, depreciation & amortization is -$13.47 M
What is Achilles Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of ACHL is -$20.42 M
What is the all time high quarterly EBITDA for Achilles Therapeutics?
Achilles Therapeutics all-time high quarterly earnings before interest, taxes, depreciation & amortization is -$5.47 M
What is Achilles Therapeutics quarterly EBITDA year-on-year change?
Over the past year, ACHL quarterly earnings before interest, taxes, depreciation & amortization has changed by -$2.05 M (-11.17%)
What is Achilles Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of ACHL is -$69.70 M
What is the all time high TTM EBITDA for Achilles Therapeutics?
Achilles Therapeutics all-time high TTM earnings before interest, taxes, depreciation & amortization is -$5.47 M
What is Achilles Therapeutics TTM EBITDA year-on-year change?
Over the past year, ACHL TTM earnings before interest, taxes, depreciation & amortization has changed by +$3.30 M (+4.52%)